HLVX vs. ORGO, TKNO, MBX, CMPS, AUTL, CYRX, ORKA, CKPT, SNDL, and TRDA
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Organogenesis (ORGO), Alpha Teknova (TKNO), MBX Biosciences (MBX), COMPASS Pathways (CMPS), Autolus Therapeutics (AUTL), Cryoport (CYRX), Oruka Therapeutics (ORKA), Checkpoint Therapeutics (CKPT), SNDL (SNDL), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs.
HilleVax (NASDAQ:HLVX) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
HilleVax has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat HilleVax's return on equity.
HilleVax has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
HilleVax currently has a consensus target price of $3.00, indicating a potential upside of 57.89%. Organogenesis has a consensus target price of $5.50, indicating a potential upside of 82.72%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than HilleVax.
Organogenesis received 87 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 65.99% of users gave Organogenesis an outperform vote while only 55.56% of users gave HilleVax an outperform vote.
86.4% of HilleVax shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 24.9% of HilleVax shares are held by company insiders. Comparatively, 36.9% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Organogenesis has higher revenue and earnings than HilleVax. Organogenesis is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
In the previous week, Organogenesis had 1 more articles in the media than HilleVax. MarketBeat recorded 6 mentions for Organogenesis and 5 mentions for HilleVax. Organogenesis' average media sentiment score of 1.62 beat HilleVax's score of 1.24 indicating that Organogenesis is being referred to more favorably in the news media.
Summary
Organogenesis beats HilleVax on 14 of the 17 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy HLVX Stock Free HLVX Stock Alerts